EPISODE · Dec 1, 2022 · 22 MIN
New Alzheimer's drug met with hope and caution
from Front Burner
Two pharmaceutical companies, Eisai and Biogen, have published the results of an 18-month human trial for their new drug, lecanemab. It's meant to treat people with early stages of Alzheimer's disease, a devastating condition that causes the majority of dementia cases and affects hundreds of thousands of Canadians. The results of the lecanemab trial are promising — the condition of people who were given the drug declined at a rate that was 27 per cent slower than those who were given a placebo. It's a glimmer of hope for those facing Alzheimer's disease, but questions about the new drug remain. Today, Mike Crawley, a reporter with CBC's health unit, is here to explain how the drug works and what it may mean for people living with Alzheimer's disease.
What this episode covers
Two pharmaceutical companies, Eisai and Biogen, have published the results of an 18-month human trial for their new drug, lecanemab. It's meant to treat people with early stages of Alzheimer's disease, a devastating condition that causes the majority of dementia cases and affects hundreds of thousands of Canadians. The results of the lecanemab trial are promising — the condition of people who were given the drug declined at a rate that was 27 per cent slower than those who were given a placebo. It's a glimmer of hope for those facing Alzheimer's disease, but questions about the new drug remain. Today, Mike Crawley, a reporter with CBC's health unit, is here to explain how the drug works and what it may mean for people living with Alzheimer's disease.
NOW PLAYING
New Alzheimer's drug met with hope and caution
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.